广东丸美生物技术股份有限公司 2024年度独立董事述职报告 本人作为广东丸美生物技术股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法 律法规、规范性文件和《公司章程》《公司独立董事工作制度》等的规定和要求，本 着客观、公正、独立的原则及对全体股东负责的态度，忠实、勤勉尽责，积极参加 公司相关会议，对董事会及专门委员会审议的相关事项发表了独立、客观的意见， 同时本人列席公司重要学术交流研讨会，主动了解公司经营情况及研发动向，运用 个人行业经验为公司提出专业建议，努力推动公司的规范运作和高质量发展，切实 维护了公司的整体利益和全体股东尤其是中小股东的合法权益。 现将 2024 年度履职情况汇报如下： 一、独立董事的基本情况 （一）独立董事个人履历 曹庸先生，出生于 1966 年 3 月，中共党员，中国国籍，无境外永久居留权，理 学博士。现任华南农业大学食品学院食品科学系教授，广州珠江啤酒股份有限公司 独立董事，幺麻子食品股份有限公司独立董事，广东惠尔泰生物科技有限公司董事， 2023 年 5 月 23 日起担任公司第四届董事会独立董事，2 ...

广东丸美生物技术股份有限公司 2024年度独立董事述职报告 作为广东丸美生物技术股份有限公司（ 以下简称"公司"）第五届董事会独立 董事，本人能严格按照《公司法》《证券法》等有关法律法规和《上市公司独立董事 管理办法》《公司章程》《公司独立董事工作制度》等文件的要求，本着客观、公正、 独立的原则，诚信、勤勉、忠实地履行职责。2024 年度，本人主动了解公司经营情 况和财务状况，积极参加公司相关会议，加强培训学习，审慎行使公司和股东所赋 予的权利，对董事会及专门委员会审议的相关事项发表了独立、客观的意见，努力 推动公司的规范运作和高质量发展，切实维护了公司的整体利益和全体股东尤其是 中小股东的合法权益。 现将 2024 年度履职情况汇报如下： 2024 年 5 月 17 日，公司召开 2023 年年度股东大会，选举本人新任第五届董事 会独立董事，本人列席了本次股东大会。任职期内，本人均积极亲自出席各次会议， 没有缺席的情况发生。具体情况如下： | | | | 参加董事会情况 | | | 参加股东大会情况 | | --- | --- | --- | --- | --- | --- | --- | | 本年应参加 ...

作为广东丸美生物技术股份有限公司（以下简称"公司"）的第四届董事会独立 董事，报告期内在任期间，本人严格遵循《公司法》《证券法》《上市公司治理准则》 《上市公司独立董事管理办法》等法律法规、规范性文件及《公司章程》《公司独立 董事工作制度》的相关规定和要求，恪守独立董事履职规范，忠实、勤勉履职，以 专业视角与严谨态度参与公司治理，主动关注公司经营状况，独立、审慎、客观地 行使独立董事权利及义务，积极维护全体股东尤其是中小股东的合法权益。 现将 2024 年度本人在任期间的履职情况汇报如下： 广东丸美生物技术股份有限公司 2024年度独立董事述职报告 一、独立董事的基本情况 （一）独立董事个人履历 毕亚林：1971 年 8 月出生，博士，拥有法律职业资格。曾任广州市水务投资集 团有限公司外部董事、广州市建筑集团有限公司外部董事，本公司独立董事，现任 广东天一星际律师事务所主任，广州交通投资集团有限公司外部董事，广州市城市 建设投资集团有限公司外部董事，山河智能装备股份有限公司独立董事，国药集团 一致药业股份有限公司独立董事,同时担任广东省政协常委、广东省党外知识分子联 谊会副秘书长、广东省律师协会副会长、广州市 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥846,648,701.63, representing a 28.01% increase compared to ¥661,391,316.33 in the same period last year[4] - Net profit attributable to shareholders was ¥135,045,089.33, up 22.07% from ¥110,628,781.43 year-over-year[4] - The diluted earnings per share increased by 21.43%, from ¥0.28 to ¥0.34[5] - Total operating revenue for Q1 2025 reached ¥846,648,701.63, a 28% increase from ¥661,391,316.33 in Q1 2024[21] - Net profit for Q1 2025 was ¥135,197,697.18, representing a 22% increase compared to ¥110,624,295.65 in Q1 2024[22] - Earnings per share for Q1 2025 were ¥0.34, compared to ¥0.28 in Q1 2024[23] Cash Flow - The net cash flow from operating activities was negative at -¥27,587,561.27, compared to -¥9,926,185.35 in the same period last year[4] - Cash generated from operating activities in Q1 2025 was ¥940,368,885.05, an increase from ¥596,906,473.84 in Q1 2024[25] - The net cash flow from operating activities was -$27,587,561.27, compared to -$9,926,185.35 in the previous period, indicating a decline in operational cash generation[26] - Total cash inflow from operating activities amounted to $954,056,827.40, up from $606,923,196.89, reflecting a significant increase of approximately 57%[26] - Cash outflow from operating activities totaled $981,644,388.67, compared to $616,849,382.24, representing an increase of about 59%[26] Assets and Liabilities - Total assets decreased by 5.59% to ¥4,779,789,213.78 from ¥5,062,564,094.81 at the end of the previous year[5] - The company's current assets totaled RMB 2,641,018,361.33, down from RMB 2,954,402,626.08 in the previous period, indicating a decline of approximately 10.6%[16] - The cash and cash equivalents decreased to RMB 1,694,566,806.00 from RMB 2,032,128,563.24, representing a reduction of about 16.6%[15] - Short-term borrowings decreased significantly from RMB 790,104,166.67 to RMB 510,000,000.00, a decline of approximately 35.4%[17] - The total liabilities of the company decreased to RMB 1,199,004,022.94 from RMB 1,616,060,597.05, reflecting a reduction of about 26%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,693[10] - The largest shareholder, Sun Huaqing, holds 72.72% of the shares, totaling 291,600,000 shares[11] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[4] Comprehensive Income - Other comprehensive income attributable to the parent company was -¥59,597.35 in Q1 2025, compared to -¥22,637.97 in Q1 2024[23] Inventory and Receivables - The company's inventory increased to RMB 243,011,003.87 from RMB 219,658,341.31, marking an increase of approximately 10.6%[16] - The accounts receivable rose to RMB 57,054,102.20 from RMB 44,998,454.03, indicating an increase of about 26.8%[16] Equity - The company's total equity attributable to shareholders was ¥3,515,392,384.83, an increase from ¥3,380,406,892.85 year-over-year[18] - The company's equity remained stable at RMB 401,000,000.00, unchanged from the previous period[17]

Financial Performance - The company's operating revenue for 2024 reached approximately CNY 2.97 billion, representing a year-on-year increase of 33.44% compared to CNY 2.23 billion in 2023[22]. - The net profit attributable to shareholders for 2024 was approximately CNY 341.63 million, up 31.69% from CNY 259.42 million in 2023[22]. - Basic earnings per share for 2024 increased to CNY 0.85, a growth of 30.77% from CNY 0.65 in 2023[24]. - The total assets of the company as of the end of 2024 were approximately CNY 5.06 billion, reflecting a 13.67% increase from CNY 4.45 billion at the end of 2023[23]. - The weighted average return on equity for 2024 was 10.08%, an increase of 2.14 percentage points compared to 7.94% in 2023[24]. - The net cash flow from operating activities for 2024 was approximately CNY 300.53 million, a decrease of 11.09% from CNY 338.02 million in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately CNY 326.58 million, a significant increase of 73.86% from CNY 187.83 million in 2023[22]. Revenue Breakdown - The main brand, Marubi, generated operating revenue of 2.055 billion RMB, accounting for 69.24% of total revenue, with a year-on-year growth of 31.69%[33]. - The PL brand achieved operating revenue of 905 million RMB, representing 30.51% of total revenue, with a year-on-year increase of 40.72%[33]. - The online revenue for the company reached 2.541 billion yuan, accounting for 85.61% of total revenue, with a year-on-year growth of 35.77%[44]. - The offline revenue reached 427 million yuan, representing 14.39% of total revenue, with a year-on-year growth of 20.79%[44]. Product Performance - The company's gross profit margin was 73.7%, up by 3.01 percentage points year-on-year, attributed to optimized product structure and cost control[34]. - The flagship product, the peptide eye cream, achieved online GMV sales of 533 million yuan, a 146% increase year-on-year[39]. - The collagen small gold needle essence achieved online GMV sales of 350 million yuan, a 96% increase year-on-year[39]. - The eye care product category saw revenue of ¥689,292,209.38, with a gross margin of 75.01%, up 2.72 percentage points compared to the previous year[59]. - The skincare product category generated ¥1,125,059,762.22 in revenue, with a gross margin of 74.92%, showing a year-on-year increase of 1.45 percentage points[59]. Research and Development - Research and development expenses were 73.54 million RMB, reflecting an 18.07% year-on-year increase, indicating continued investment in R&D[34]. - The company applied for 86 new domestic and international patents, with a total of 596 patents filed by the end of the reporting period[38]. - The number of R&D personnel is 94, accounting for 8% of the total workforce[68]. Market Strategy - The company has maintained a consistent growth of approximately 30% in both revenue and profit for eight consecutive quarters[35]. - The company is focusing on key technologies and industrial applications, particularly in recombinant collagen technology, to enhance its competitive edge in the cosmetics market[35]. - The marketing strategy is centered on a dual-core approach of "brand power + product power," optimizing the marketing matrix and enhancing business collaboration[101]. Corporate Governance - The governance structure is compliant with relevant laws and regulations, ensuring clear responsibilities and decision-making processes[109]. - The company held one annual and one temporary shareholders' meeting during the reporting period, with all resolutions passed legally and effectively[110]. - The company maintains independence from its controlling shareholders, ensuring autonomous operations and decision-making[113]. - The company has a diverse board with members holding various academic and professional backgrounds, enhancing its governance[117]. Environmental and Social Responsibility - The company invested approximately ¥2.92 million in environmental protection during the reporting period[149]. - The company reduced carbon emissions by 664.63 tons through various measures, including the use of clean energy and digital energy management[153]. - The company has been recognized as a "provincial-level green factory" in Guangdong and has received carbon neutrality certification for three products[152]. Shareholder and Dividend Information - The company implemented a cash dividend policy, distributing a total of 208,520,000.00 RMB in cash dividends for the 2023 fiscal year, which represents 80.38% of the net profit attributable to the parent company's shareholders[139]. - For the first three quarters of 2024, the company plans to distribute 100,250,000.00 RMB in cash dividends, accounting for 41.98% of the net profit attributable to the parent company's shareholders during that period[139]. Risks and Challenges - The company faces increasing market competition due to the rapid growth of e-commerce and rising costs, alongside intensified competition from both domestic and foreign brands[103]. - There is a risk of strategic execution not meeting expectations, despite efforts to enhance product innovation and brand building[104]. - The company is actively working to retain talent through effective compensation and incentive policies, but still faces the risk of talent loss[105].

关于广东丸美生物技术股份有限公司 2024 年度募集资金存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"保荐人"）作为广东丸美生物技术股份 有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票并上市的保荐 人，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规定，就丸美 生物 2024 年度募集资金的存放与使用情况进行了核查，具体情况如下： 中信证券股份有限公司 公司募集资金项目本期投入募集资金 43,156,850.13 元，累计已使用募集资 金 498,456,729.20 元，加上扣除手续费后累计利息收入净额 88,947,751.10 元，减 除现金管理专户余额 75,000,000.00 元，募集资金账户 2024 年 12 月 31 日余额为 305,493,021.90 元。 二、募集资金的存放和管理情况 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会证监许可〔2019〕917 号 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-010 广东丸美生物技术股份有限公司 关于2025年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2025 年第一季度主要经营数据 披露如下： | | | | 主要产品 | 产量（支） | 销量（支） | 营业收入（元） | | --- | --- | --- | --- | | 眼部类 | 2,659,613 | 1,468,904 | 213,971,133 | | 护肤类 | 3,383,905 | 3,607,220 | 328,758,702 | | 洁肤类 | 1,000,338 | 1,005,227 | 69,728,678 | | 美容类 | 2,480,977 | 2,821,371 | 225,779,898 | 二、2025 年第一季度公司主要产品和原材料的价格变动情况 （一）主要产品价格变 ...

广东丸美生物技术股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况报告 根据《公司法》《证券法》《上市公司治理准则》《国有企业、上市公司选聘会 计师事务所管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》及《公司章程》等相关规定和要求，广东丸美生物技术股份有限公司（本文简 称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将 董事会审计委员会对会计师事务所 2024 年度履职评估及履行监督职责的情况汇报 如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 华兴会计师事务所（特殊普通合伙）（以下简称"华兴事务所"）前身系福建华 兴会计师事务所，创立于 1981 年，隶属福建省财政厅。1998 年 12 月，与原主管 单位福建省财政厅脱钩，改制为福建华兴有限责任会计师事务所。2009 年 1 月， 更名为福建华兴会计师事务所有限公司。2013 年 12 月，转制为福建华兴会计师事 务所（特殊普通合伙）。2019 年 7 月，更名为华兴会计师事务所（特殊普通合伙）。 华兴会计师事务所（特殊普通合伙）为特殊普通合伙企业，注册 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-005 广东丸美生物技术股份有限公司 关于2024年第四季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将公司 2024 年第四季度主要经营数据 披露如下： 一、2024 年第四季度公司主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（支） | 销量（支） | 营业收入（元） | | --- | --- | --- | --- | | 眼部类 | 2,642,161 | 2,222,029 | 327,069,541 | | 护肤类 | 5,457,052 | 3,885,270 | 339,577,670 | | 洁肤类 | 1,077,312 | 1,089,406 | 64,324,337 | | 美容类 | 4,110,767 | 4,238,018 | 279,278,003 | 二、2024 年第四季度公司 ...